Transarterial Chemoembolization versus Radiofrequency Ablation for Small Hepatocellular Carcinomas with Discrepant Features on Computed Tomography and Magnetic Resonance Imaging.
- Author:
Young Youn CHO
1
;
Jung Hee KWON
;
Jeong Hoon LEE
;
Jeong Min LEE
;
Jae Young LEE
;
Hyo Cheol KIM
;
Jin Wook CHUNG
;
Won mook CHOI
;
Eun Ju CHO
;
Su Jong YU
;
Yoon Jun KIM
;
Jung Hwan YOON
;
Chung Yong KIM
;
Hyo Suk LEE
Author Information
1. Department of Internal Medicine and Liver Research Institute, Seoul, Korea. pindra@empal.com
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Multidetector computed tomography;
Magnetic resonance imaging
- MeSH:
Carcinoma, Hepatocellular*;
Catheter Ablation*;
Humans;
Magnetic Resonance Imaging*;
Multidetector Computed Tomography;
Prospective Studies;
Recurrence;
Treatment Failure
- From:Journal of Liver Cancer
2015;15(1):19-29
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: This study compared the outcomes of patients with small hepatocellular carcinomas (HCCs) who were treated using transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). METHODS: This was a post-hoc analysis of a prospective study that evaluated the diagnostic efficacy of magnetic resonance imaging (MRI) and computed tomography (CT). We analyzed 41 small hepatic nodules in 32 patients that showed typical radiologic hallmarks on both CT and gadoxate-enhanced MRI (typical nodules) and 25 small hepatic nodules from 22 patients that showed atypical radiologic hallmarks on CT and typical radiologic hallmarks on MRI (discrepant nodules). RESULTS: There were no significant differences in the baseline characteristics of the patients with typical and discrepant nodules. Complete response rates 1 month after TACE or RFA were 75.0% (18/24) and 94.1% (16/17; P=0.20), respectively, for the patients with typical nodules and 58.8% (10/17) and 100% (8/8; P=0.05), respectively, for the patients with discrepant nodules. Treatment failure rates after TACE or RFA were 33.3% (8/24) and 5.8% (1/17; P=0.15), respectively, for the patients with typical nodules and 47.0% (8/17) and 0.0% (0/8; P=0.02), respectively, for the patients with discrepant nodules. Among patients achieving complete response, there were no significant differences in the risk of marginal recurrence. CONCLUSIONS: RFA provided higher complete response rates and significantly lower treatment failure rates than TACE for patients with discrepant nodules of HCC. Therefore, a treatment modality such as RFA may be preferable for small HCCs which show discrepancy on two imaging modalities.
